Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

LGNDNYSE / NASDAQHealthcareMid cap

$286.85-$0.09 (0.0%)

Last close · Data as of Nov 20, 2026

Market cap
$4.7B
P/E
38.0x
EV / EBITDA
25.3x
Revenue
$268.1M
Net margin
46.4%
ROCE
3.1%

+44.1% over the last year

Ligand Pharmaceuticals Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-6.4%
3M
-0.2%
6M
+31.7%
1Y
+44.1%
5Y
+184.0%

52-week range

Day change -$0.09 (0.0%) from $287 to $287 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LGND, bought on each weekday since 2021.

News & filings

What Ligand Pharmaceuticals Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was 0.40 times net profit in fiscal 2025.

Strengths (1)

  • Operating profit was 34.7 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Read moreShow less

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Sector
Healthcare
Shares outstanding
19.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.7B
P/E
38.0x
P/B
4.6x
EV / EBITDA
25.3x
EV / Sales
18.7x
P/S
17.6x
52-week high
$322.75
52-week low
$181.65

Profitability

Operating margin
17.6%
Net margin
46.4%
EBITDA margin
73.7%
ROE
12.2%
ROCE
3.1%
ROA
8.0%
Asset turnover
0.17

Growth

Revenue
$268.1M
Revenue growth, 1Y
60.4%
Revenue CAGR, 3Y
11.0%
Net profit growth, 1Y
-3186.6%
Free cash flow
$38.0M

Solvency

Current ratio
22.23
Debt / Equity
0.44
Debt / Assets
0.29
CFO / Net profit
0.40
Cash / Market cap
3.7%

Where the revenue went

Of every $100 of FY2025 revenue, $46 was left as net income.

Ligand Pharmaceuticals Incorporated income statement flow, FY2025
Ligand Pharmaceuticals Incorporated income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$14.6M
RevenueGross profit$253.5M
Gross profitResearch and development$81.2M
Gross profitSelling, general and administrative$92.5M
Gross profitOther operating expenses$32.7M
Gross profitOperating income$47.2M
Operating incomePretax income$47.2M
Interest and other incomePretax income$111.8M
Pretax incomeTax and other$34.5M
Pretax incomeNet income$124.5M

Revenue and net profit

Revenue grew 60.4% in FY2025; net profit is the dashed line.

Ligand Pharmaceuticals Incorporated revenue and net profit by fiscal year
Ligand Pharmaceuticals Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$196.2M-$33.4M
FY2023$131.3M$52.2M
FY2024$167.1M-$4.0M
FY2025$268.1M$124.5M

Cash flows

FY2025: $49.4M from operations, $38.0M free after investment (dashed).

Ligand Pharmaceuticals Incorporated operating and free cash flow by fiscal year
Ligand Pharmaceuticals Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$137.8M$119.9M
FY2023$49.6M-$4.3M
FY2024$97.0M$77.4M
FY2025$49.4M$38.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$268.1M+60.4%1Y
EBITDA
$197.4M+384.0%1Y
Net profit
$124.5M
Cash from operations
$49.4M-49.1%1Y
Free cash flow
$38.0M-50.9%1Y
Revenue CAGR, 3Y
11.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$268.1M$197.4M$124.5M$38.0M12.2%+60.4%-3186.6%

Monthly returns

Month-by-month returns of LGND across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.6B
Liabilities$543.4M
Equity$1.0B
Paid-in capital$400.6M
Retained earnings$608.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LGND highlighted.

P/E against peers

LGND trades at 38.0x earnings against a peer median of 31.9x (a 19% premium).

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Ligand Pharmaceuticals IncorporatedLGNDthis companyP/E ↑ premium$4.7B38.0x4.6x12.2%25.3x
Apellis Pharmaceuticals, Inc.APLS$5.3B234.6x14.2x6.0%75.2x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Amneal Pharmaceuticals, Inc.AMRX$4.3B59.9x-60.9x-101.8%11.1x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
Peer median—31.9x2.7x4.0%14.3x

Year-to-date ROI

LGND since 1 January, against earlier years.

Historical volatility

LGND's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Ligand Pharmaceuticals Incorporated operating margin by fiscal year
Ligand Pharmaceuticals Incorporated operating margin by fiscal year
DateOperating margin
FY20221.5%
FY20237.5%
FY202413.8%
FY202517.6%
LineFY2025
Cost of revenueCost Of Revenue$14.6M
Gross profitGross Profit$253.5M
Operating expensesOperating Expense$206.3M
Research and developmentResearch And Development$81.2M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$32.7M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$32.7M
Amortization$32.7M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$32.7M
Total expensesTotal Expenses$220.9M
Pretax incomePretax Income$159.0M

Learn while you research

Academy chapters picked for Ligand Pharmaceuticals Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 38.0, learn when high multiples are justified.6 min read
  3. 03 Growth Investing60% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →